Gregory R. Bluemling

2.9k total citations · 2 hit papers
15 papers, 901 citations indexed

About

Gregory R. Bluemling is a scholar working on Infectious Diseases, Epidemiology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Gregory R. Bluemling has authored 15 papers receiving a total of 901 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Infectious Diseases, 7 papers in Epidemiology and 4 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Gregory R. Bluemling's work include Viral Infections and Vectors (6 papers), SARS-CoV-2 and COVID-19 Research (4 papers) and Respiratory viral infections research (4 papers). Gregory R. Bluemling is often cited by papers focused on Viral Infections and Vectors (6 papers), SARS-CoV-2 and COVID-19 Research (4 papers) and Respiratory viral infections research (4 papers). Gregory R. Bluemling collaborates with scholars based in United States, Switzerland and India. Gregory R. Bluemling's co-authors include George R. Painter, Alexander A. Kolykhalov, Michael G. Natchus, Zachary M. Sticher, Mark A. Lockwood, Jeong-Joong Yoon, Märt Toots, Richard K. Plemper, Robert M. Cox and Deborah G. Mitchell and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of Virology.

In The Last Decade

Gregory R. Bluemling

15 papers receiving 886 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Small-Molecule Antiviral β- d - N ⁴ -Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance

2019 255 citations Maria L. Agostini, Andrea J. Pruijssers et al. Journal of Virology profile →
Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia

2019 233 citations Märt Toots, Jeong-Joong Yoon et al. Science Translational Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gregory R. Bluemling United States	10	663	320	179	115	59	15	901
Ilaria Vicenti Italy	19	670 1.0×	222 0.7×	123 0.7×	140 1.2×	45 0.8×	75	943
Jeong-Joong Yoon United States	16	455 0.7×	434 1.4×	180 1.0×	52 0.5×	75 1.3×	22	912
Calli M. Lear-Rooney United States	8	707 1.1×	223 0.7×	229 1.3×	87 0.8×	33 0.6×	8	1.0k
Ruchao Peng China	21	653 1.0×	275 0.9×	392 2.2×	96 0.8×	106 1.8×	33	1.1k
Zachary M. Sticher United States	10	433 0.7×	242 0.8×	119 0.7×	40 0.3×	37 0.6×	14	601
Aesop Cho United States	15	450 0.7×	254 0.8×	326 1.8×	77 0.7×	83 1.4×	24	906
Ulrik Fahnøe Denmark	17	494 0.7×	303 0.9×	184 1.0×	57 0.5×	117 2.0×	71	1.0k
Rana Abdelnabi Belgium	20	894 1.3×	216 0.7×	238 1.3×	361 3.1×	97 1.6×	50	1.3k
Amy C. Shurtleff United States	19	1.0k 1.5×	338 1.1×	229 1.3×	291 2.5×	22 0.4×	30	1.4k
Zhinan Jin United States	13	534 0.8×	378 1.2×	179 1.0×	84 0.7×	173 2.9×	17	888

Countries citing papers authored by Gregory R. Bluemling

Since Specialization

Citations

This map shows the geographic impact of Gregory R. Bluemling's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gregory R. Bluemling with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gregory R. Bluemling more than expected).

Fields of papers citing papers by Gregory R. Bluemling

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gregory R. Bluemling. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gregory R. Bluemling. The network helps show where Gregory R. Bluemling may publish in the future.

Co-authorship network of co-authors of Gregory R. Bluemling

This figure shows the co-authorship network connecting the top 25 collaborators of Gregory R. Bluemling. A scholar is included among the top collaborators of Gregory R. Bluemling based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gregory R. Bluemling. Gregory R. Bluemling is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Westover, Jonna B., Alexander A. Kolykhalov, Gregory R. Bluemling, et al.. (2025). Oral 4′-fluorouridine rescues mice from advanced lymphocytic choriomeningitis virus infection. Antiviral Research. 237. 106122–106122. 1 indexed citations

Westover, Jonna B., Cigdem Alkan, Arnaud J. Van Wettere, et al.. (2024). Modeling Heartland virus disease in mice and therapeutic intervention with 4′-fluorouridine. Journal of Virology. 98(4). e0013224–e0013224. 8 indexed citations

Sourimant, Julien, Carolin M. Lieber, Megha Aggarwal, et al.. (2022). 4'-Fluorouridine is an oral antiviral that blocks respiratory syncytial virus and SARS-CoV-2 replication.. PubMed. 375(6577). 161–167. 45 indexed citations

Sourimant, Julien, Carolin M. Lieber, Megha Aggarwal, et al.. (2022). 4′-Fluorouridine is an oral antiviral that blocks respiratory syncytial virus and SARS-CoV-2 replication. Science. 375(6577). 161–167. 79 indexed citations

Bluemling, Gregory R., Michael G. Natchus, Wendy Painter, et al.. (2022). The prophylactic and therapeutic efficacy of the broadly active antiviral ribonucleoside N-Hydroxycytidine (EIDD-1931) in a mouse model of lethal Ebola virus infection. Antiviral Research. 209. 105453–105453. 9 indexed citations

Kolykhalov, Alexander A., Erica L. Andres, James D. Chappell, et al.. (2020). Small-Molecule Antiviral β-d-N4-Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance. UNC Libraries. 2 indexed citations

Mayers, Douglas L., Gregory R. Bluemling, Alexander A. Kolykhalov, et al.. (2020). ATI-2173, a Novel Liver-Targeted Non-Chain-Terminating Nucleotide for Hepatitis B Virus Cure Regimens. Antimicrobial Agents and Chemotherapy. 64(9). 20 indexed citations

Agostini, Maria L., Andrea J. Pruijssers, James D. Chappell, et al.. (2019). Small-Molecule Antiviral β- d - N ⁴ -Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance. Journal of Virology. 93(24). 255 indexed citations breakdown →

Toots, Märt, Jeong-Joong Yoon, Robert M. Cox, et al.. (2019). Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Science Translational Medicine. 11(515). 233 indexed citations breakdown →

10.

Painter, George R., Richard A. Bowen, Gregory R. Bluemling, et al.. (2019). The prophylactic and therapeutic activity of a broadly active ribonucleoside analog in a murine model of intranasal venezuelan equine encephalitis virus infection. Antiviral Research. 171. 104597–104597. 81 indexed citations

11.

Sticher, Zachary M., Deborah G. Mitchell, Gregory R. Bluemling, et al.. (2019). Analysis of the Potential for N ⁴ -Hydroxycytidine To Inhibit Mitochondrial Replication and Function. Antimicrobial Agents and Chemotherapy. 64(2). 25 indexed citations

12.

Kuhlmann, F, John I. Robinson, Gregory R. Bluemling, et al.. (2017). Antiviral screening identifies adenosine analogs targeting the endogenous dsRNA Leishmania RNA virus 1 (LRV1) pathogenicity factor. Proceedings of the National Academy of Sciences. 114(5). E811–E819. 36 indexed citations

13.

Bluemling, Gregory R., et al.. (2017). Simple In Vitro Assay To Evaluate the Incorporation Efficiency of Ribonucleotide Analog 5′-Triphosphates into RNA by Human Mitochondrial DNA-Dependent RNA Polymerase. Antimicrobial Agents and Chemotherapy. 62(2). 9 indexed citations

14.

Welch, Stephen R., Lisa Wiggleton Guerrero, Ayan K. Chakrabarti, et al.. (2016). Lassa and Ebola virus inhibitors identified using minigenome and recombinant virus reporter systems. Antiviral Research. 136. 9–18. 57 indexed citations

15.

Bluemling, Gregory R., et al.. (2016). Analysis of Ribonucleotide 5′-Triphosphate Analogs as Potential Inhibitors of Zika Virus RNA-Dependent RNA Polymerase by Using Nonradioactive Polymerase Assays. Antimicrobial Agents and Chemotherapy. 61(3). 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact